Viridian治疗机构通过出售1 140万股,每股22美元,筹集了2.51亿美元,为甲状腺眼病治疗和研究供资。 Viridian Therapeutics raised $251 million by selling 11.4 million shares at $22 each to fund therapies for thyroid eye disease and research.

Viridian治疗公司以每股22.00美元的价格公开出价1 140万股,在开销前筹集了约2.51亿美元,如果承保人行使选择权,可再筹集170万股。 Viridian Therapeutics priced a public offering of 11.4 million shares at $22.00 each, raising about $251 million before expenses, with an additional 1.7 million shares available if underwriters exercise their option. 由Jeffery和其他人牵头的这项提议定于2025年10月23日结束,其收益将用于资助两种甲状腺眼病疗法的商业启动、正在进行的研究和公司的一般使用。 The offering, led by Jefferies and others, is set to close on October 23, 2025, and proceeds will fund the commercial launch of two therapies for thyroid eye disease, ongoing research, and general corporate use. 该公司正在推进稀有和严重疾病的多种治疗,包括两个第3阶段试验,并取得积极的上线结果。 The company is advancing multiple treatments for rare and serious diseases, including two phase 3 trials with positive topline results. 出价在证交会登记,任何出售的证券将有一个正式计划书管辖。 The offering is registered with the SEC, and a formal prospectus will govern any securities sold.